Khalid Iqbal, MD
Nephrology · Atlanta, GANPI 1598755993
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,837 of the $2,046 with a category attached, or 89.8%. It is spread thinly across 18 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $626, 5.8 times the $107 reported in 2019.
Across 85 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$298
- Bayer$262
- Mallinckrodt Hospital Products Inc.$237
- Amgen$179
- Aurinia Pharma U.S., Inc.$156
- Vantive US Healthcare LLC$146
- plus $769 from 12 others
Across 13 payments — averaging $3610.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$47K
What the payments were for
- Food & beverage$1,83790%
- Education$21010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $298 |
| Bayer | 8 | $262 |
| Mallinckrodt Hospital Products Inc. | 6 | $237 |
| Amgen | 8 | $179 |
| Aurinia Pharma U.S., Inc. | 7 | $156 |
| Vantive US Healthcare LLC | 2 | $146 |
| Calliditas Therapeutics US Inc. | 5 | $119 |
| Baxter Healthcare | 2 | $111 |
| Fresenius USA Marketing, Inc. | 4 | $101 |
| Akebia Therapeutics Inc | 4 | $98 |
| Ardelyx, Inc. | 3 | $85 |
| AstraZeneca | 4 | $77 |
| Travere Therapeutics, Inc. | 14 | $66 |
| Novartis | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| GSK | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$135
- Kerendia$103
How this compares
$2,046 in reported general payments places this provider in the 55th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $147,011 |
| JardianceEmpagliflozin | 54 | $72,203 |
| VelphoroSucroferric Oxyhydroxide | 11 | $32,972 |
| LokelmaSodium Zirconium Cyclosilicate | 29 | $29,689 |
| ProcritEpoetin Alfa | 21 | $18,885 |
| Sevelamer Carbonate | 36 | $10,215 |
| Nifedipine ErNifedipine | 64 | $3,821 |
| Bumetanide | 146 | $3,525 |
| Torsemide | 125 | $3,349 |
| Calcium Acetate | 20 | $3,011 |
| Calcitriol | 112 | $2,195 |
| Atorvastatin Calcium | 245 | $2,044 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,141 |
| Hydralazine Hcl | 53 | $1,034 |
| Amlodipine Besylate | 178 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $77 | $176,700141 claims |
| Fresenius USA Marketing, Inc.Velphoro | $101 | $32,97211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Sheldon ShoreAtlanta$474K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Tarik LalwaniAtlanta$69K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.